Health
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease – nejm.org
Original Article from The New England Journal of Medicine — Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
From the DanaFarber/Boston Childrens Cancer and Blood Disorders Center, Harvard Medical School (E.B.E., L.E.L., A.B., C.B., M.F.C., B.M., K.B., S.-Y.P., W.B.L., C.D., M.M.H., D.A.W.), the Harvard Stem Cell Institute, Harvard Medical School (A.B., C.B.), the Gene Therapy Program, DanaFarber/Boston Childrens Cancer and Blood Disorders Center (A.B., M.F.C., B.M., E.M., A.F., S.-Y.P., C.D., D.A.W.), the Division of Hematology, Brigham and Womens Hospital, Harvard Medical School (M. Achebe), the Connell…
-
Business17 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
General24 hours agoMichael Beatty, veteran current affairs journalist and animal welfare advocate, dies aged 76
-
Noosa News14 hours agoTips to improve engagement – Proctor
-
Noosa News16 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland